BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15561890)

  • 1. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.
    Choi C; Witzens M; Bucur M; Feuerer M; Sommerfeldt N; Trojan A; Ho A; Schirrmacher V; Goldschmidt H; Beckhove P
    Blood; 2005 Mar; 105(5):2132-4. PubMed ID: 15561890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.
    Noto H; Takahashi T; Makiguchi Y; Hayashi T; Hinoda Y; Imai K
    Int Immunol; 1997 May; 9(5):791-8. PubMed ID: 9184925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
    Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
    Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies.
    Ocadlikova D; Kryukov F; Mollova K; Kovarova L; Buresdova I; Matejkova E; Penka M; Buchler T; Hajek R; Michalek J
    Neoplasma; 2010; 57(5):455-64. PubMed ID: 20568900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
    Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
    Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
    Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
    J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
    Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
    Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
    Tyler EM; Jungbluth AA; Gnjatic S; O'Reilly RJ; Koehne G
    Cancer Immunol Res; 2014 Jun; 2(6):547-58. PubMed ID: 24894092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients.
    Feuerer M; Rocha M; Bai L; Umansky V; Solomayer EF; Bastert G; Diel IJ; Schirrmacher V
    Int J Cancer; 2001 Apr; 92(1):96-105. PubMed ID: 11279612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].
    Ocadlíková D; Kovárová L; Hájek R; Michálek J
    Klin Onkol; 2008; 21(2):59-65. PubMed ID: 19102213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow.
    Feuerer M; Beckhove P; Bai L; Solomayer EF; Bastert G; Diel IJ; Pedain C; Oberniedermayr M; Schirrmacher V; Umansky V
    Nat Med; 2001 Apr; 7(4):452-8. PubMed ID: 11283672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma.
    Cloosen S; Gratama J; van Leeuwen EB; Senden-Gijsbers BL; Oving EB; von Mensdorff-Pouilly S; Tarp MA; Mandel U; Clausen H; Germeraad WT; Bos GM
    Br J Haematol; 2006 Nov; 135(4):513-6. PubMed ID: 17010104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
    Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.
    Takahashi T; Makiguchi Y; Hinoda Y; Kakiuchi H; Nakagawa N; Imai K; Yachi A
    J Immunol; 1994 Sep; 153(5):2102-9. PubMed ID: 8051415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
    Carmon L; Avivi I; Kovjazin R; Zuckerman T; Dray L; Gatt ME; Or R; Shapira MY
    Br J Haematol; 2015 Apr; 169(1):44-56. PubMed ID: 25496030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
    Front Immunol; 2019; 10():1792. PubMed ID: 31428094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.